DNA Diagnostics Center Partners with Contraline in ADAMTM Clinical Trial, Testing Revolutionary Male Contraceptive

FAIRFIELD, Ohio--(BUSINESS WIRE)-- [DNA Diagnostics Center, Inc. (DDC), a global leader in consumer testing services, and part of the global network of Eurofins laboratories, announces its collaboration with Contraline, a clinical-stage medical device company specializing in reproductive health innovation, in their first of a kind clinical trial for ADAMTM, an investigational male contraceptive device.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240620661738/en/

ADAMTM represents a significant advancement in male contraception. It involves injecting a proprietary hydrogel into the vas deferens, providing long-lasting and non-hormonal contraception for male patients. ADAMTM occludes sperm transport within the vas deferens, similar to a vasectomy, however, is designed to be non-permanent and easier to reverse. This innovative approach aims to offer men an alternative to traditional contraceptive methods such as condoms and vasectomy. Contraline’s ADAMTM Study, a First-in-Human trial conducted in Australia, has fully enrolled 25 patients into the study and is now focusing on monitoring the long-term safety and efficacy of the device.

Contraline received approval from the Human Research Ethics Committee (HREC) to integrate DDC’s SpermCheck Vasectomy® into the ADAMTM Study protocol. SpermCheck Vasectomy® is an accurate and convenient at-home test kit designed to confirm the success of vasectomy procedures by detecting the presence of sperm in semen samples. SpermCheck Vasectomy® is a leading male fertility brand in the US, with over one million units sold, and is currently an investigational device in Australia.